These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 9450156

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of the efficacy of pivagabine on insomnia associated with mood disorders.
    Negri L.
    Arzneimittelforschung; 1997 Nov; 47(11A):1322-5. PubMed ID: 9450157
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of phospholipid liposomes in the treatment of neuropsychological disorders associated with the menopause: a double-blind, randomised, placebo-controlled study.
    Rachev E, Nalbansky B, Kolarov G, Agrosì M.
    Curr Med Res Opin; 2001 Nov; 17(2):105-10. PubMed ID: 11759177
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 8. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C, Olivieri L, Di Loreto G, Dionisio P.
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Duloxetine in treatment of anxiety symptoms associated with depression.
    Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ.
    Depress Anxiety; 2003 Sep; 18(2):53-61. PubMed ID: 12964171
    [Abstract] [Full Text] [Related]

  • 12. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine.
    Addolorato G, Balducci G, Capristo E, Attilia ML, Taggi F, Gasbarrini G, Ceccanti M.
    Alcohol Clin Exp Res; 1999 Oct; 23(10):1596-604. PubMed ID: 10549990
    [Abstract] [Full Text] [Related]

  • 13. [Wuling Capsule for climacteric patients with depression and anxiety state: a randomized, positive parallel controlled trial].
    Wang XJ, Li J, Zou QD, Jin L.
    Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1042-6. PubMed ID: 19912735
    [Abstract] [Full Text] [Related]

  • 14. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J, Deramciclane Dose-Finding Study Group.
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression.
    Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A.
    Nord J Psychiatry; 2007 Dec; 61(5):343-8. PubMed ID: 17990195
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of soy isoflavones for depressive symptoms of the climacteric syndrome.
    de Sousa-Muñoz RL, Filizola RG.
    Maturitas; 2009 May 20; 63(1):89-93. PubMed ID: 19339127
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P.
    J Clin Psychopharmacol; 2006 Dec 20; 26(6):653-6. PubMed ID: 17110825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.